Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 450 full-time employees. The company went IPO on 2017-12-07. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
Mr. Everett Cunningham is the President of Quanterix Corp, joining the firm since 2026.
What is the price performance of QTRX stock?
The current price of QTRX is $3.58, it has increased 5.87% in the last trading day.
What are the primary business themes or industries for Quanterix Corp?
Quanterix Corp belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Quanterix Corp market cap?
Quanterix Corp's current market cap is $168.4M
Is Quanterix Corp a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Quanterix Corp, including 0 strong buy, 0 buy, 6 hold, 1 sell, and 0 strong sell